Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most
@article{TLCR96694, author = {Eric Santoni-Rugiu and Jens Benn Sørensen and Edyta Maria Urbanska}, title = {Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most}, journal = {Translational Lung Cancer Research}, volume = {14}, number = {2}, year = {2025}, keywords = {}, abstract = {}, issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/96694} }